{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Mutation&page=2", "query": { "condition": "Gene Mutation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Mutation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:58:07.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01801111", "title": "A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2013-06-20", "completion_date": "2017-10-27", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Fullerton, California • Orange, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Luis Obispo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01801111" }, { "nct_id": "NCT00999609", "title": "Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inherited Retinal Dystrophy Due to RPE65 Mutations", "Leber Congenital Amaurosis" ], "interventions": [ { "name": "AAV2-hRPE65v2,voretigene neparvovec-rzyl", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Spark Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 31, "start_date": "2012-10", "completion_date": "2030-01", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Philadelphia, Pennsylvania", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00999609" }, { "nct_id": "NCT00968864", "title": "T-cell Depleted Alternative Donor Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Myelodysplastic Syndrome", "Lymphomas", "Bone Marrow Failure", "Hemoglobinopathy", "Immune Deficiency", "Osteopetrosis" ], "interventions": [ { "name": "CliniMACS® (T cell depletion)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 53, "start_date": "2009-08", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2022-04-22", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00968864" }, { "nct_id": "NCT02074839", "title": "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Acute Myeloid Leukemia (AML)", "Untreated AML", "Other IDH1-mutated Positive Hematologic Malignancies", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "AG-120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2014-03-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074839" }, { "nct_id": "NCT03780257", "title": "Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Retinitis Pigmentosa", "Usher Syndrome Type 2", "Deaf Blind", "Retinal Disease", "Eye Diseases", "Eye Diseases, Hereditary", "Eye Disorders Congenital", "Vision Disorders" ], "interventions": [ { "name": "QR-421a", "type": "DRUG" }, { "name": "Sham-procedure (dose cohort 1&2 only)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ProQR Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-03-06", "completion_date": "2021-10-14", "has_results": false, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03780257" }, { "nct_id": "NCT03597581", "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer", "Gastrointestinal Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Gastric Cancer", "Gastric Neoplasm", "KRAS Mutation-Related Tumors", "CRC", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "ompenaclid", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inspirna, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2018-06-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 17, "location_summary": "Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03597581" }, { "nct_id": "NCT03755102", "title": "A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "EGFR Gene Mutation", "Lung Cancer", "Lung Cancer Metastatic" ], "interventions": [ { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-11-21", "completion_date": "2023-07-07", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03755102" }, { "nct_id": "NCT04006301", "title": "First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Advanced Solid Tumors", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "JNJ-74699157", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-07-26", "completion_date": "2020-07-13", "has_results": false, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 4, "location_summary": "Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04006301" }, { "nct_id": "NCT03786692", "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Carcinoma of Lung, TNM Stage 4" ], "interventions": [ { "name": "Arm A", "type": "DRUG" }, { "name": "Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2019-09-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786692" }, { "nct_id": "NCT01280565", "title": "Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Masitinib", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AB Science", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2011-01", "completion_date": "2019-08", "has_results": false, "last_update_posted_date": "2020-11-05", "last_synced_at": "2026-06-25T17:58:07.602Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01280565" } ] }